9783725856237 - management of dyslipidaemias: enhancing lipid modification to reduce cardiovascular risk (10 risultati)

- Rilegato
- Print on Demand
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.Grand Eagle Retail
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 64,24
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: new. Hardcover. Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmenta…l, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

- Rilegato
- Print on Demand
Da: PBShop.store US, Wood Dale, IL, U.S.A.PBShop.store US
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 64,26
Spedizione gratuitaSpedito in U.S.A.Quantità: Più di 20 disponibili
HRD. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Rilegato
- Print on Demand
Da: PBShop.store UK, Fairford, GLOS, Regno UnitoPBShop.store UK
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 60,69
EUR 5,81 spedizioneSpedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
HRD. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Rilegato
- Print on Demand
Da: Majestic Books, Hounslow, , Regno UnitoMajestic Books
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 85,24
EUR 7,52 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 4 disponibili
Condizione: New. Print on Demand.

- Rilegato
- Print on Demand
Da: Books Puddle, New York, NY, U.S.A.Books Puddle
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 91,36
EUR 3,44 spedizioneSpedito in U.S.A.Quantità: 4 disponibili
Condizione: New. Print on Demand.

- Rilegato
- Print on Demand
Da: Biblios, frankfurt am main, HESSE, GermaniaBiblios
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 85,64
EUR 9,95 spedizioneSpedito da Germania a U.S.A.Quantità: 4 disponibili
Condizione: New. PRINT ON DEMAND.

- Rilegato
- Print on Demand
Da: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 77,24
EUR 31,92 spedizioneSpedito da Australia a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: new. Hardcover. Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmenta…l, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

- Rilegato
- Print on Demand
Da: CitiRetail, Stevenage, Regno UnitoCitiRetail
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 68,53
EUR 42,82 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: new. Hardcover. Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmenta…l, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.

- Rilegato
- Print on Demand
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 72,93
EUR 62,88 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol…, the identification of biological, environmental, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management.

- Rilegato
- Print on Demand
Da: preigu, Osnabrück, Germaniapreigu
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 89,60
EUR 70,00 spedizioneSpedito da Germania a U.S.A.Quantità: 5 disponibili
Buch. Condizione: Neu. Management of Dyslipidaemias | Enhancing Lipid Modification to Reduce Cardiovascular Risk | Buch | Englisch | 2025 | MDPI AG | EAN 9783725856237 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.